--- title: "Intelligent Bio Solutions | 8-K: FY2026 Revenue: USD 4.215 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/296358963.md" datetime: "2026-08-19T12:53:21.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296358963.md) - [en](https://longbridge.com/en/news/296358963.md) - [zh-HK](https://longbridge.com/zh-HK/news/296358963.md) generator: "portal-rs" --- # Intelligent Bio Solutions | 8-K: FY2026 Revenue: USD 4.215 M Revenue: As of FY2026, the actual value is USD 4.215 M. EPS: As of FY2026, the actual value is USD -8.44. EBIT: As of FY2026, the actual value is USD -12.57 M. ### Fiscal Year 2026 Financial Highlights #### Gross Profit and Margin Gross profit for fiscal year 2026 was $2,049,994, marking a 64% increase from $1,246,859 in fiscal year 2025. The gross profit margin expanded to 48.63% in fiscal year 2026, an improvement of 778 basis points from 40.85% in fiscal year 2025. Cost of revenue was -$2,165,181 in fiscal year 2026, compared to -$1,805,673 in fiscal year 2025. #### Operating Expenses and Loss Total operating expenses for fiscal year 2026 amounted to -$15,335,855, up from -$12,742,918 in fiscal year 2025. This included selling, general and administrative expenses of -$10,502,161 (fiscal year 2025: -$8,918,468), development and regulatory approval expenses of -$3,371,292 (fiscal year 2025: -$2,396,513), depreciation and amortization of -$1,163,847 (fiscal year 2025: -$1,207,875), and impairment of long-lived assets of -$298,555 (fiscal year 2025: -$220,062). The loss from operations was -$12,608,085 in fiscal year 2026, compared to -$10,679,158 in fiscal year 2025. #### Other Income/Expense and Net Loss Government support income was $677,776 in fiscal year 2026, down from $816,901 in fiscal year 2025. Interest expense was -$10,736 in fiscal year 2026, decreasing from -$26,339 in fiscal year 2025. Realized foreign exchange showed a gain of $39,820 in fiscal year 2026, compared to a loss of -$911 in fiscal year 2025. Interest income was $110,329 in fiscal year 2026, slightly up from $101,522 in fiscal year 2025. Total other income, net, was $139,413 in fiscal year 2026, up from $74,272 in fiscal year 2025. The net loss for fiscal year 2026 was -$12,468,672, compared to -$10,604,886 in fiscal year 2025. The net loss attributable to Intelligent Bio Solutions Inc. was -$12,430,975 in fiscal year 2026, compared to -$10,568,733 in fiscal year 2025. #### Comprehensive Loss Foreign currency translation resulted in a loss of -$218,242 in fiscal year 2026, contrasting with a gain of $384,670 in fiscal year 2025. The comprehensive loss for fiscal year 2026 was -$12,686,914, compared to -$10,220,216 in fiscal year 2025. The comprehensive loss attributable to Intelligent Bio Solutions Inc. was -$12,649,217 in fiscal year 2026, compared to -$10,184,063 in fiscal year 2025. ### Operational Metrics The reader installed base grew 22% year-over-year to 1,886 units as of June 30, 2026, from 1,545 units as of June 30, 2025. Total consumable cartridges increased by 35% to 106,500 units in fiscal year 2026, up from 78,750 units in fiscal year 2025. The company reported 502 active customers as of June 30, 2026. ### Outlook and Guidance For fiscal year 2027, Intelligent Bio Solutions Inc. aims to sustain operational improvements driving gross margin expansion, accelerate commercial growth, and advance its FDA regulatory program toward planned U.S. market entry. The company has completed all clinical data collection for its FDA 510(k) clinical study program, with data analysis underway, and remains on track for its FDA submission in the second half of calendar 2026. The transition to Syrma Johari for manufacturing is expected to transform the cost structure and support long-term margin improvement. ### Related Stocks - [INBS.US](https://longbridge.com/en/quote/INBS.US.md) ## Related News & Research - [Intelligent Bio Solutions GAAP EPS of -$8.44, revenue of $4.22M](https://longbridge.com/en/news/296440057.md) - [INBS: Revenue up 38% to $4.2M, gross margin 48.63%, FDA submission on track for late 2026](https://longbridge.com/en/news/296357255.md) - [Intelligent Bio Solutions completes usability study for FDA filing of codeine fingerprint drug test](https://longbridge.com/en/news/294968543.md) - [Intelligent Bio Solutions completes interference study for fingerprint codeine screening system ahead of FDA filing](https://longbridge.com/en/news/294693815.md) - [Intelligent Bio Solutions completes 1,600+ precision tests to bolster FDA 510(k) submission](https://longbridge.com/en/news/293344850.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**